CNS Pharmaceuticals, Inc.
CNSP
$5.78
-$0.16-2.69%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 25.55% | 17.15% | 10.74% | 1.55% | 13.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.60% | 5.92% | 7.28% | -22.72% | -2.57% |
| Operating Income | -8.60% | -5.92% | -7.28% | 22.72% | 2.57% |
| Income Before Tax | -8.03% | -5.58% | -6.68% | 23.37% | 3.22% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.03% | -5.58% | -6.68% | 23.37% | 3.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.03% | -5.58% | -6.68% | 23.37% | 3.22% |
| EBIT | -8.60% | -5.92% | -7.28% | 22.72% | 2.57% |
| EBITDA | -8.53% | -5.91% | -7.27% | 22.73% | 2.57% |
| EPS Basic | 89.19% | 85.94% | 78.37% | 56.53% | -- |
| Normalized Basic EPS | 89.19% | 85.94% | 78.37% | 56.53% | -- |
| EPS Diluted | 89.19% | 85.94% | 78.37% | 56.53% | -- |
| Normalized Diluted EPS | 89.19% | 85.94% | 78.37% | 56.53% | -- |
| Average Basic Shares Outstanding | 1,100.87% | 528.08% | 1,303.65% | 3,303.55% | -- |
| Average Diluted Shares Outstanding | 1,100.87% | 528.08% | 1,303.65% | 3,303.55% | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |